The effect of a 5HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease

Andrzej Rydzewski, Tetsumei Urano, Takashi Hachiya, Hiroshi Kaneko, Shozo Baba, Yumiko Takada, Akikazu Takada

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The effect of a new, specific 5-HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function and serotonin levels in both plasma and whole blood in Buerger's disease, was assessed in a pilot study. We investigated 10 patient suffering from Buerger's disease. Sarpogrelate in a dose of 3 x 100mg a day was given p.o. for a period of 8 weeks. It was well tolerated and no major side effects were noted. It was judged to be effective in some patients as assessed by its effect on both subjective complaints and objective evaluation of ankle pressure index (API). Sarpogrelate induced a significant decrease in plasma serotonin (5-HT) concentration starting after the 4th week which lasted through to the 8th week of the study, whereas plasma tryptophan concentration increased significantly after 2 and 4 weeks. There were no changes in plasma 5-HIAA concentration. On the other hand whole blood 5-HT concentration increased significantly after 2 weeks, and there was also a tendency to increase in whole blood tryptophan concentration (p = 0.052). Platelet aggregation induced by ADP and collagen did not show any statistically significant changes. Surprisingly, platelet aggregation induced by serotonin increased significantly after 2 weeks and even more so after 4 weeks of treatment, and then it returned to baseline values after 8 weeks. There was no effect on platelet count, APTT, TT and fibrinogen concentration.

Original languageEnglish
Pages (from-to)445-452
Number of pages8
JournalThrombosis Research
Volume84
Issue number6
DOIs
Publication statusPublished - 1996 Dec 15

Fingerprint

Thromboangiitis Obliterans
Serotonin
Blood Platelets
Platelet Aggregation
Tryptophan
Serotonin 5-HT2 Receptor Antagonists
Therapeutics
Hydroxyindoleacetic Acid
Platelet Count
Ankle
Adenosine Diphosphate
Fibrinogen
Collagen
sarpogrelate
Pressure

Keywords

  • 5-HT antagonist
  • Buerger's disease
  • platelet function
  • sarpogrelate
  • serotonin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology

Cite this

The effect of a 5HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease. / Rydzewski, Andrzej; Urano, Tetsumei; Hachiya, Takashi; Kaneko, Hiroshi; Baba, Shozo; Takada, Yumiko; Takada, Akikazu.

In: Thrombosis Research, Vol. 84, No. 6, 15.12.1996, p. 445-452.

Research output: Contribution to journalArticle

Rydzewski, Andrzej ; Urano, Tetsumei ; Hachiya, Takashi ; Kaneko, Hiroshi ; Baba, Shozo ; Takada, Yumiko ; Takada, Akikazu. / The effect of a 5HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease. In: Thrombosis Research. 1996 ; Vol. 84, No. 6. pp. 445-452.
@article{99a78b079c1b4220bfdd4aac193301ab,
title = "The effect of a 5HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease",
abstract = "The effect of a new, specific 5-HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function and serotonin levels in both plasma and whole blood in Buerger's disease, was assessed in a pilot study. We investigated 10 patient suffering from Buerger's disease. Sarpogrelate in a dose of 3 x 100mg a day was given p.o. for a period of 8 weeks. It was well tolerated and no major side effects were noted. It was judged to be effective in some patients as assessed by its effect on both subjective complaints and objective evaluation of ankle pressure index (API). Sarpogrelate induced a significant decrease in plasma serotonin (5-HT) concentration starting after the 4th week which lasted through to the 8th week of the study, whereas plasma tryptophan concentration increased significantly after 2 and 4 weeks. There were no changes in plasma 5-HIAA concentration. On the other hand whole blood 5-HT concentration increased significantly after 2 weeks, and there was also a tendency to increase in whole blood tryptophan concentration (p = 0.052). Platelet aggregation induced by ADP and collagen did not show any statistically significant changes. Surprisingly, platelet aggregation induced by serotonin increased significantly after 2 weeks and even more so after 4 weeks of treatment, and then it returned to baseline values after 8 weeks. There was no effect on platelet count, APTT, TT and fibrinogen concentration.",
keywords = "5-HT antagonist, Buerger's disease, platelet function, sarpogrelate, serotonin",
author = "Andrzej Rydzewski and Tetsumei Urano and Takashi Hachiya and Hiroshi Kaneko and Shozo Baba and Yumiko Takada and Akikazu Takada",
year = "1996",
month = "12",
day = "15",
doi = "10.1016/S0049-3848(96)00212-5",
language = "English",
volume = "84",
pages = "445--452",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - The effect of a 5HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease

AU - Rydzewski, Andrzej

AU - Urano, Tetsumei

AU - Hachiya, Takashi

AU - Kaneko, Hiroshi

AU - Baba, Shozo

AU - Takada, Yumiko

AU - Takada, Akikazu

PY - 1996/12/15

Y1 - 1996/12/15

N2 - The effect of a new, specific 5-HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function and serotonin levels in both plasma and whole blood in Buerger's disease, was assessed in a pilot study. We investigated 10 patient suffering from Buerger's disease. Sarpogrelate in a dose of 3 x 100mg a day was given p.o. for a period of 8 weeks. It was well tolerated and no major side effects were noted. It was judged to be effective in some patients as assessed by its effect on both subjective complaints and objective evaluation of ankle pressure index (API). Sarpogrelate induced a significant decrease in plasma serotonin (5-HT) concentration starting after the 4th week which lasted through to the 8th week of the study, whereas plasma tryptophan concentration increased significantly after 2 and 4 weeks. There were no changes in plasma 5-HIAA concentration. On the other hand whole blood 5-HT concentration increased significantly after 2 weeks, and there was also a tendency to increase in whole blood tryptophan concentration (p = 0.052). Platelet aggregation induced by ADP and collagen did not show any statistically significant changes. Surprisingly, platelet aggregation induced by serotonin increased significantly after 2 weeks and even more so after 4 weeks of treatment, and then it returned to baseline values after 8 weeks. There was no effect on platelet count, APTT, TT and fibrinogen concentration.

AB - The effect of a new, specific 5-HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function and serotonin levels in both plasma and whole blood in Buerger's disease, was assessed in a pilot study. We investigated 10 patient suffering from Buerger's disease. Sarpogrelate in a dose of 3 x 100mg a day was given p.o. for a period of 8 weeks. It was well tolerated and no major side effects were noted. It was judged to be effective in some patients as assessed by its effect on both subjective complaints and objective evaluation of ankle pressure index (API). Sarpogrelate induced a significant decrease in plasma serotonin (5-HT) concentration starting after the 4th week which lasted through to the 8th week of the study, whereas plasma tryptophan concentration increased significantly after 2 and 4 weeks. There were no changes in plasma 5-HIAA concentration. On the other hand whole blood 5-HT concentration increased significantly after 2 weeks, and there was also a tendency to increase in whole blood tryptophan concentration (p = 0.052). Platelet aggregation induced by ADP and collagen did not show any statistically significant changes. Surprisingly, platelet aggregation induced by serotonin increased significantly after 2 weeks and even more so after 4 weeks of treatment, and then it returned to baseline values after 8 weeks. There was no effect on platelet count, APTT, TT and fibrinogen concentration.

KW - 5-HT antagonist

KW - Buerger's disease

KW - platelet function

KW - sarpogrelate

KW - serotonin

UR - http://www.scopus.com/inward/record.url?scp=0030589195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030589195&partnerID=8YFLogxK

U2 - 10.1016/S0049-3848(96)00212-5

DO - 10.1016/S0049-3848(96)00212-5

M3 - Article

VL - 84

SP - 445

EP - 452

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 6

ER -